Drug Class: SGLT2 Inhibitor (Sodium-Glucose Cotransporter-2 Inhibitor) | Form: Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Diajard 10mg Tablet? Diajard 10mg contains Empagliflozin — an SGLT2 inhibitor that lowers blood sugar through a completely insulin-independent mechanism — directly increasing urinary glucose excretion regardless of insulin levels or pancreatic function. This unique kidney-based action makes it effective even in patients with significant insulin resistance and provides additional cardiovascular and renal benefits beyond simple glucose lowering that are not seen with most other antidiabetic medicines. Clinical trials have demonstrated that Empagliflozin significantly reduces cardiovascular death, hospitalisation for heart failure, and kidney disease progression in high-risk Type 2 diabetic patients — making it one of the few antidiabetic medicines with proven organ-protective benefits beyond glycaemic control. It is used alongside diet and exercise as monotherapy or in combination with other antidiabetic medicines under diabetologist supervision.
What is Diajard 10mg Used For?
- Type 2 diabetes mellitus — improving glycaemic control alongside diet and exercise (ذیابیطس ٹائپ 2 میں بلڈ شوگر کنٹرول)
- Cardiovascular risk reduction — reducing cardiovascular death and hospitalisation in diabetic patients with established heart disease (دل کی بیماری میں موت کا خطرہ کم کرنا)
- Heart failure with reduced ejection fraction — reducing hospitalisation and cardiovascular death risk
- Diabetic nephropathy — slowing progression of kidney disease in Type 2 diabetic patients (ذیابیطس میں گردوں کی حفاظت)
- Combination therapy — alongside Metformin, DPP-4 inhibitors, sulphonylureas, or insulin
- Weight management benefit — modest weight reduction through caloric loss via urinary glucose excretion
How Does it Work? Empagliflozin selectively and reversibly inhibits SGLT2 transporters in the proximal renal tubule — blocking approximately 90% of glucose reabsorption from filtered urine back into the bloodstream. This allows large amounts of glucose — typically 60 to 80 grams daily — to be excreted in the urine rather than reabsorbed, directly lowering blood glucose independently of insulin. This insulin-independent mechanism means it works effectively regardless of disease duration or degree of beta cell failure. Beyond glucose lowering, SGLT2 inhibition reduces intraglomerular pressure protecting kidney function, decreases plasma volume reducing cardiac preload, lowers uric acid levels, and produces modest reductions in blood pressure and body weight — contributing to the significant cardiovascular and renal protective benefits observed in clinical trials.
Dosage and Administration
⚠️ Monitor kidney function before and regularly during treatment — reduced efficacy and increased risk below GFR 45ml/min. Maintain adequate hydration throughout treatment — volume depletion risk. Temporarily stop before major surgery or prolonged fasting — DKA risk. Carry fast-acting glucose for hypoglycaemia if combined with insulin or sulphonylurea. Check urine and genital hygiene regularly — increased UTI and genital infection risk.
| Indication | Usual Adult Dose | Frequency | Notes |
|---|---|---|---|
| Type 2 diabetes — initial | 10mg | Once daily | With or without food — any time of day |
| Cardiovascular risk reduction | 10mg | Once daily | With or without other antidiabetics |
| Heart failure | 10mg | Once daily | Under cardiologist supervision |
| Diabetic nephropathy | 10mg | Once daily | Regular kidney function monitoring |
| Dose escalation if needed | 25mg | Once daily | If 10mg tolerated and more control needed |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Empagliflozin | 10mg |
Who Should NOT Take Diajard 10mg?
- Allergy to Empagliflozin or any SGLT2 inhibitor
- Type 1 diabetes mellitus — significantly increased diabetic ketoacidosis risk
- Diabetic ketoacidosis — active or suspected DKA requires immediate insulin therapy
- Severe kidney impairment — GFR below 30ml/min; significantly reduced efficacy and increased risk
- Recurrent urinary tract infections — SGLT2 inhibitors increase UTI frequency
- Recurrent genital fungal infections — significantly increased risk with glucosuria
- Severe liver impairment — not recommended
- Pregnancy and breastfeeding — insulin preferred during pregnancy
- Children under 18 years — safety not established
- Significant volume depletion or hypotension — correct before starting
Side Effects
Common: Genital fungal infections — thrush in women and balanitis in men (جنسی اعضاء کی پھپھوندی — صفائی سے روکا جا سکتا ہے), urinary tract infections — burning urination and increased frequency (پیشاب کی نالی کا انفیکشن), increased urination — expected from glucose excretion mechanism (پیشاب زیادہ آنا), mild dizziness from modest blood pressure lowering, mild thirst.
Serious — Stop and seek emergency help immediately: Diabetic ketoacidosis — nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, and confusion even with near-normal blood sugar (ذیابیطس کیٹواسیڈوسس — فوری ہسپتال جائیں), Fournier's gangrene — rare but life-threatening genital and perineal necrotising infection requiring emergency surgery (جنسی اعضاء کے قریب شدید انفیکشن — فوری ہسپتال جائیں), severe urinary tract infection spreading to kidneys — pyelonephritis with high fever and back pain (گردے کا شدید انفیکشن — فوری مدد لیں), acute kidney injury — significantly reduced urination with dehydration (فوری ڈاکٹر کو بتائیں), significant hypotension with fainting particularly in elderly or volume-depleted patients (بے ہوشی — فوری مدد لیں), lower limb amputation risk — inspect feet regularly for wounds or infections.
Drug Interactions
| Medicine | Interaction |
|---|---|
| Insulin / Sulphonylureas | Increased hypoglycaemia risk — dose reduction of insulin or sulphonylurea typically required |
| Diuretics (Furosemide, Thiazides) | Additive volume depletion and hypotension — dehydration significantly increases acute kidney injury risk |
| Antihypertensives | Additive blood pressure lowering — increased hypotension risk particularly in elderly patients |
| NSAIDs (Ibuprofen, Diclofenac) | Increased acute kidney injury risk — avoid regular combined use especially in volume-depleted patients |
| ACE inhibitors / ARBs | Additive kidney protection benefit — but combined volume depletion increases acute kidney injury risk; monitor closely |
| Corticosteroids (Prednisolone) | Significantly raise blood glucose — reduce Empagliflozin effectiveness; also increase DKA risk |
| Lithium | Empagliflozin increases urinary Lithium excretion — may reduce Lithium levels; monitor |
| Rifampicin | Reduces Empagliflozin blood levels — reduced glycaemic effectiveness |
| Alcohol (شراب) | Increases volume depletion and DKA risk — avoid excessive consumption |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: Why does Diajard 10mg cause genital infections and how can this be prevented? Empagliflozin causes glucose to be excreted in urine — creating a sugar-rich environment in the genital area that promotes fungal and bacterial growth. Maintaining excellent genital hygiene, staying well hydrated, and promptly treating any early infection symptoms significantly reduces this risk. Most infections are mild and respond well to standard antifungal or antibiotic treatment.
Q: What is diabetic ketoacidosis with SGLT2 inhibitors and why is it dangerous? Empagliflozin can rarely trigger DKA — a dangerous condition where the body burns fat for energy producing harmful ketones — sometimes even when blood sugar is near-normal making it harder to recognise. Symptoms include nausea, vomiting, abdominal pain, and difficulty breathing. Stop Diajard immediately and seek emergency care if these symptoms develop — particularly during illness, surgery, fasting, or significantly reduced food intake.
Q: Can Diajard 10mg help with weight loss in Type 2 diabetic patients? Empagliflozin produces modest but clinically meaningful weight reduction — typically 2 to 3 kg — through daily caloric loss of the excreted glucose in urine. While not primarily a weight loss medicine, this weight benefit contributes to overall cardiovascular risk reduction and improved insulin sensitivity in overweight Type 2 diabetic patients alongside its glycaemic and organ-protective effects.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.